Ignite Creation Date:
2024-05-05 @ 4:54 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00332761
Status:
COMPLETED
Last Update Posted:
2021-01-27
First Post:
2006-06-01
Brief Title:
Caduet in an Untreated Subject Population
Sponsor:
Pfizers Upjohn has merged with Mylan to form Viatris Inc
Organization:
Pfizer
Study Overview
Official Title:
An 8-Week Randomized Double-Blind Placebo-Controlled Trial Examining The Efficacy And Safety Of Caduet In Simultaneously Achieving Blood Pressure And Lipid Goals In An Untreated Hypertensive And Dyslipidemic Subject Population CUSP - Caduet in Untreated Subject Population
Status:
COMPLETED
Status Verified Date:
2021-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CUSP
Brief Summary:
The purpose of this study is to determine if Caduet will lower blood pressure to 14090 mmHg and lower LDL Cholesterol to 100 mgdL in subjects with hypertension and dyslipidemia who are not currently being treated for these medical conditions
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None